SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes.

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes.

Enfortumab vedotin plus pembrolizumab is more effective than chemotherapy as first-line treatment for metastatic urothelial cancer, data suggest.

Virtual reality relaxation program can reduce pain intensity, with significant changes in brain functional connectivity patterns.

Converting from the long-acting ESA methoxy polyethylene glycol-epoetin-ß (MPG-EPO) to thrice weekly vadadustat is feasible for the hemodialysis population.

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

(HealthDay News) — Microplastic exposure may increase the risk for chronic diseases, according to a study presented at the annual meeting of the American College of Cardiology, held from March 29 to ...

(HealthDay News) — Despite increased participation in U.S. long-distance running races, cardiac arrest incidence remains stable, according to a study published online March 30 in the Journal of the ...

The FDA has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

Atrasentan reduced urine protein-to-creatinine ratio by 38% compared with 3% for placebo at week 36. The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ...

Secondary rectal cancer tumors that develop years after prostate cancer radiation therapy appear to differ in distinct ways from primary rectal cancers.